Bernd Seizinger

Dr. Bernd R.
Seizinger is an Independent Director at Turbine Simulated Cell Technologies Ltd., an Independent Director at Aptose Biosciences, Inc., an Independent Director at BioInvent International AB, an Independent Director at Oncolytics Biotech, Inc., an Executive Chairman & Chief Executive Officer at CryptoMedix, Inc. and an Independent Director at Aprea Therapeutics, Inc. He is on the Board of Directors at Turbine Simulated Cell Technologies Ltd., Aptose Biosciences, Inc., BioInvent International AB, Oncolytics Biotech, Inc., Aprea Therapeutics AB, Aprea Therapeutics, Inc., TriMod Therapeutics Ltd., Karolinska Institutet and Oxford BioTherapeutics Ltd. Dr. Seizinger was previously employed as a Non-Executive Director by Bionor Pharma ASA, a Member-Supervisory Board by Agennix AG, an Independent Director by BioXell SpA, a President & Chief Executive Officer by GPC Biotech AG, a VP-Oncology Drug Discovery & Academic Alliances by Bristol-Myers Squibb Pharmaceutical Research Institute, an Associate Professor-Neuroscience by Harvard Medical School, a Director-Molecular Neuro-Oncology Laboratory by The General Hospital Corp., a Chief Scientific Officer & Executive VP by Oscient Pharmaceuticals Corp., and a Principal by Princeton University.
He also served on the board at Nykode Therapeutics ASA and Santhera Pharmaceuticals Holding AG.
He received his doctorate degree from the Max-Planck-Institute for Molecular Genetics and a doctorate degree from Ludwig-Maximilians-Universität München.